Koroush Khalighi

Dr. Koroush Khalighi


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 October 2018 in PLOS ONE
Verified
Journal Article
Open access
PDF file
ZMZhiyuan Ma
Zhiyuan Ma
PWPing Wang
Ping Wang
ZGZehui Gao
Zehui Gao
RWRuobing Wang
Ruobing Wang
KKKoroush Khalighi
Koroush Khalighi
Warfarin dosing remains challenging due to narrow therapeutic index and highly individual variability. Incorrect warfarin dosing is associated with devastating adverse events. Remarkable efforts have been made to develop the machine learning based warfarin dosing algorithms incorporating clinical factors and genetic variants such as polymorphisms in CYP2C9 and VKORC1. The most widely validated pharmacogenetic algorithm is the IWPC algorithm based on multivariate linear regression (MLR). However, with only a single algorithm, the prediction performance may reach an upper limit even with optimal parameters. Here, we present novel algorithms using stacked generalization frameworks to estimate the warfarin dose, within which different types of machine learning algorithms function together through a meta-machine learning model to maximize the prediction accuracy. Compared to the IWPC-derived MLR algorithm, Stack 1 and 2 based on stacked generalization frameworks performed significantly better overall. Subgroup analysis revealed that the mean of the percentage of patients whose predicted dose of warfarin within 20% of the actual stable therapeutic dose (mean percentage within 20%) for Stack 1 was improved by 12.7% (from 42.47% to 47.86%) in Asians and by 13.5% (from 22.08% to 25.05%) in the low-dose group compared to that for MLR, respectively. These data suggest that our algorithms would especially benefit patients requiring low warfarin maintenance dose, as subtle changes in warfarin dose could lead to adverse clinical events (thrombosis or bleeding) in patients with low dose. Our study offers novel pharmacogenetic algorithms for clinical trials and practice.

25 October 2013 in Pacing and Clinical Electrophysiology
Verified
Journal Article
Closed access
PDF file
KKKoroush Khalighi
Koroush Khalighi
TAThein Tun Aung
Thein Tun Aung
FEFarhad Elmi
Farhad Elmi

1 January 2016 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
PDF file
SOSwe Zin Mar Win Htut Oo
Swe Zin Mar Win Htut Oo
KKKoroush Khalighi
Koroush Khalighi
AKArchana Kodali
Archana Kodali
CMCho May
Cho May
TAThein Tun Aung
Thein Tun Aung
RSRichard Snyder
Richard Snyder
Omnious T-wave inversions: Wellens’ syndrome revisited

3 July 2017 in Journal of Community Hospital Internal Medicine Perspectives
Verified
Journal Article
Open access
SMSeyed Abbas Mirabbasi
Seyed Abbas Mirabbasi
KKKoroush Khalighi
Koroush Khalighi
YWYin Wu
Yin Wu
SWStanley Walker
Stanley Walker
BKBahar Khalighi
Bahar Khalighi
GCGang Cheng
Gang Cheng
Background: Clopidogrel (Plavix) is an antiplatelet medication that is routinely used in patients with cardiovascular disease. Cytochrome P2C19 enzymes play a major role in its metabolism, which determines its varied therapeutic level and its effectiveness. Objectives: To customize clopidogrel therapy and evaluate its efficacy by using CYP2C19 genotypic and phenotypic information to improve clinical outcomes in patients. Methods: A total of 465 patients with underlying cardiovascular disease were selected from our out-patient cardiology clinic. DNA sequences of CYP2C19 were analyzed in 465 patients. Results: Of 465 patients, 183 were wild-type homozygous (*1/*1) and 18.8% gain-of function and 19.8% loss-of-function alleles in our patient population The following changes were made: 1) Switching to prasugrel in patients whose genotype noted them to be "Slow metabolizers. This medication adjustment improved clinical outcomes in this patient group. 2) Discontinuing or lowering clopidogrel doses in patients whose genotypes noted them to be "Fast or ultra-fast metabolizes" to decrease bleeding risk. For those who were not on clopidogrel but carried abnormal allele(s), "clopidogrel caution" was documented. These individuals were followed up for 3 years and there has not been any cardiac clinical symptoms, cardiac death or excessive bleeding reported. Conclusions: Given the varied effectiveness of clopidogrel due to its metabolism by CYP2C19 enzyme, and the relatively high frequency of both gain-of-function (18.8%) and loss-of-function (19.8%) alleles in our patient population, we believe that genotyping CYP2C19 is clinically important in order to improve patient outcomes and minimize patient risk.

6 September 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZMZhiyuan Ma
Zhiyuan Ma
GCGang Cheng
Gang Cheng
PWPing Wang
Ping Wang
BKBahar Khalighi
Bahar Khalighi
KKKoroush Khalighi
Koroush Khalighi
Warfarin is a widely used anticoagulant with a narrow therapeutic index and large interpatient variability in the therapeutic dose. Complications from inappropriate warfarin dosing are one of the most common reasons for emergency room visits. Approximately one third of warfarin dose variability results from common genetic variants. Therefore, it is very necessary to recognize warfarin sensitivity in individuals caused by genetic variants. Based on combined polymorphisms in CYP2C9 and VKORC1, we established a clinical classification for warfarin sensitivity. In the International Warfarin Pharmacogenetic Consortium (IWPC) with 5542 patients, we found that 95.1% of the Black in the IWPC cohort were normal warfarin responders, while 74.8% of the Asian were warfarin sensitive (P < 0.001). Moreover, we created a clinical algorithm to predict warfarin sensitivity in individual patients using logistic regression. Compared to a fixed-dose approach, the clinical algorithm provided significantly better performance. In addition, we validated the derived clinical algorithm using the external Easton cohort with 106 chronic warfarin users. The AUC was 0.836 vs. 0.867 for the Easton cohort and the IWPC cohort, respectively. With the use of this algorithm, it is very likely to facilitate patient care regarding warfarin therapy, thereby improving clinical outcomes.

3 February 2018 in Journal of Clinical Laboratory Analysis
Verified
Journal Article
Closed access
PDF file
KKKoroush Khalighi
Koroush Khalighi
GCGang Cheng
Gang Cheng
SMSeyedabbas Mirabbasi
Seyedabbas Mirabbasi
BKBahar Khalighi
Bahar Khalighi
YWYin Wu
Yin Wu
WFWuqiang Fan
Wuqiang Fan